Werewolf Therapeutics Inc
HOWL1.240USD
+0.080+6.90%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
55.59MMarket Cap
LossP/E TTM
More Details of Werewolf Therapeutics Inc Company
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Company Info
Ticker SymbolHOWL
Company nameWerewolf Therapeutics Inc
IPO dateApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Number of employees46
Security typeOrdinary Share
Fiscal year-endApr 30
Address200 Talcott Avenue
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone16179520555
Websitehttps://werewolftx.com/
Ticker SymbolHOWL
IPO dateApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
19.93%
Venture Capital
14.89%
Hedge Fund
12.83%
Investment Advisor
9.66%
Research Firm
5.33%
Corporation
4.56%
Individual Investor
1.51%
Bank and Trust
0.08%
Family Office
0.02%
Other
31.19%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
157
30.87M
68.80%
-5.72M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
PFM Health Sciences, LP
2.51M
5.59%
-398.94K
-13.73%
Mar 31, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.48M
3.3%
-29.02K
-1.92%
Mar 31, 2025
Rubric Capital Management LP
1.33M
2.97%
--
--
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
DFA Dimensional US Core Equity Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
